Applied Sciences · 2023 · 13 citations · 71 references
MedicineNuclear MedicineOncologyDiagnostic ImagingDiagnostic Nuclear MedicineMolecular ImagingOncologic Nuclear ImagingPositron Emission TomographyProstate CancerProstate Cancer ImagingProstate ImagingTumor ImagingCastration-resistant Prostate Cancer TherapyMetastatic Castration-resistant Prostate CancerProstate-specific Antigen - Targeted TherapyProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen Positron Emission TomographyPsma-pet ImagingPsma-targeted TherapyTherapy Response Monitoring
This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly in mCRPCT (metastatic castration-resistant prostate cancer). This review describes the widely used Radium-223 and the novel trend in the TAT field with a special focus on prostate-specific membrane antigen (PSMA)-based alpha therapy. With this in-depth discussion on the growing field of PSMA-based alpha therapy, we aim also to analyze the most useful diagnostic tools in the patient selection and in the treatment monitoring. We explored the diagnostic tools used in clinical practice and in research settings in order to clarify the imaging procedures that may support the PSMA-based TAT management, including both the patient’s selection and the therapy response monitoring, with a special focus on diagnostic PSMA-PET/CT imaging. Further multicenter trials are needed, but a better understanding of the strengths and limitations of molecular imaging in PSMA-based TAT management may help in creating an effective therapeutic algorithm for mCRPC and designing a rational approach to treatment.
71
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.5K citations · Full text
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker, Sten Nilsson, Daniel Heinrich et al. · New England Journal of Medicine · 2013 · 3.3K citations
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text